| All 2008 Releases |
|---|
| 05/12/08 |
Isis Reports Financial Results and Highlights for First Quarter of 2008
|
|
| |
CARLSBAD, Calif., May 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended March 31, 2008. The Company finished the quarter with a pro forma net operating loss (NOL) of $5.1 million, excluding compensation expense related to stock options, co...
|
|
| 05/07/08 |
Webcast Alert: Isis Pharmaceuticals Announces First Quarter 2008 Financial Results Conference Call
|
|
| |
CARLSBAD, Calif., May 7, 2008 (PrimeNewswire via COMTEX News Network) -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announces the following webcast:
What: Isis Pharmaceuticals' First Quarter 2008 Financial Results
When: Monday, May 12, 2008, at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
How: Live on the Intern...
|
|
| 05/06/08 |
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases
|
|
| |
CAMBRIDGE, Mass. & CARLSBAD, Calif., May 06, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA (miRNA) therapeutics, announced today that it has obtained exclusive rights from Sta...
|
|
| 04/25/08 |
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
|
|
| |
CARLSBAD, Calif. and CAMBRIDGE, Mass., April 25, 2008 /PRNewswire via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corp. (Nasdaq: GENZ) announced today that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate...
|
|
| 04/18/08 |
Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
|
|
| |
CARLSBAD, Calif., April 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) presented the results of two studies designed to assess the impact of lowering apoB-100 on atherosclerosis at the 2008 Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Conference in Atlanta, Georgia. The data we...
|
|
| 04/17/08 |
Regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance
|
|
| |
CARLSBAD, Calif. & CAMBRIDGE, Mass., Apr 17, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call this morning, Thursday, April 17, at 8:00 a.m. ET to discuss its new alliance with Glaxo...
|
|
| 04/17/08 |
GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases
|
|
| |
LONDON & PHILADELPHIA & CARLSBAD, Calif., Apr 17, 2008 (BUSINESS WIRE) -- GlaxoSmithKline (GSK) and Regulus Therapeutics LLC (Regulus) today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus...
|
|
| 04/14/08 |
Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
|
|
| |
CARLSBAD, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced additional results from its ongoing Phase 2 open-label extension (OLE) study of mipomersen in patients with familial hypercholesterolemia (FH). In FH patients exposed to mipomersen for as long as 16 months, the safe...
|
|
| 04/08/08 |
Bristol-Myers Squibb Selects Isis Drug Targeting Pcsk9 as Development Candidate For Prevention and Treatment of Cardiovascular Disease
|
|
| |
CARLSBAD, Calif., April 8, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Bristol-Myers Squibb Company (NYSE: BMY) has selected a compound from the companies' collaboration as a development candidate. As a result, Isis will receive a $2 million milestone payment. The two c...
|
|
| 03/13/08 |
Isis Reports Financial Results and Highlights for Fiscal year 2007
|
|
| |
CARLSBAD, Calif., March 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2007 financial results and business highlights. The Company finished a very successful year by meeting its 2007 pro forma net operating loss (NOL) guidance with an NOL of $29.0 million. The 2007 NOL was 54...
|
|
| 03/03/08 |
Webcast Alert: Isis Pharmaceuticals Announces Financial Results and Highlights for Fiscal Year 2007 Conference Call
|
|
| |
CARLSBAD, Calif., Mar 3, 2008 (PrimeNewswire via COMTEX News Network) -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announces the following webcast:
What: Isis Pharmaceuticals' Financial Results and Highlights for Fiscal
Year 2007
When: Thursday, March 13, 2008, at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
...
|
|
| 02/12/08 |
Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis' Pathogen Identification Technology
|
|
| |
CARLSBAD, Calif., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that its majority-owned subsidiary, Ibis Biosciences, Inc. (Ibis), has been awarded two new Phase 2 Small Business Innovation Research (SBIR) grants and a new government contract totaling up to approximately $2....
|
|
| 02/11/08 |
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
|
|
| |
CAMBRIDGE, Mass. & CARLSBAD, Calif., Feb 11, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA therapeutics, announced today the appointment of Peter S. Linsley, Ph.D., as Chief S...
|
|
| 02/01/08 |
Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
|
|
| |
CAMBRIDGE, Mass. and CARLSBAD, Calif., Feb 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that they have received clearance under the Hart-Scott-Rodino Antitrust Improvements Act for their collaboration, which was announced on January 7, 2008. Bas...
|
|
| 01/31/08 |
Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
|
|
| |
CARLSBAD, Calif., Jan 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Abbott is investing up to $40 million in Ibis Biosciences, Inc., an Isis subsidiary. The investment will allow Ibis to further develop the Ibis T5000(TM) Biosensor System, which offers a unique solution for...
|
|
| 01/07/08 |
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
|
|
| |
CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that they have entered a major strategic alliance in which Genzyme will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk ca...
|
|
| Showing 1-16 of 16 releases |
Page: 1 |
|
|
** Even though press releases remain on our site, we do not update information in individual releases to reflect subsequent developments. Content and information present in each press release was factually accurate on the issue date. **
